10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat

Shares of 10x Genomics (NASDAQ:TXG) gapped up before the market opened on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $17.51, but opened at $19.24. 10x Genomics shares last traded at $19.2650, with a volume of 943,596 shares changing hands.

The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. The business had revenue of $166.03 million during the quarter, compared to the consensus estimate of $160.35 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.40) earnings per share.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q4 results beat expectations — 10x reported revenue of $166.03M (vs. $160.35M est.) and a loss per share of ($0.13) versus consensus ($0.19), with revenue roughly flat year‑over‑year; investors view this as evidence of demand resilience. 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
• Positive Sentiment: Earnings call / transcript highlighted the beat and management’s commentary on execution and product adoption (read for color on management’s tone and strategic priorities). 10x Genomics (TXG) Q4 2025 Earnings Transcript
• Positive Sentiment: New scientific collaboration (PharosAI) using 10x’s Xenium platform could expand long‑term addressable market in cancer research, a potential revenue driver beyond 2026. UK-Backed PharosAI Cancer Data Project Using Xenium Might Change The Case For Investing In 10x Genomics (TXG)
• Neutral Sentiment: FY‑2026 revenue guidance set at $600M–$625M, roughly in line with sell‑side consensus ($624.2M) — guidance reduces near‑term forecasting surprise but leaves upside dependent on execution. 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
• Neutral Sentiment: Street reaction mixed — TD Cowen kept a Hold rating but raised the price target to $19, signaling cautious respect for the beat but limited conviction on upside. Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside
• Negative Sentiment: Management rolled out a new pricing strategy that analysts flagged as an “earnings test” — pricing changes could create near‑term volatility and make 2026 growth visibility more uncertain. 10X Genomics faces earnings test as new pricing strategy debuts
• Negative Sentiment: Analyst commentary emphasizes limited 2026 growth visibility and constrained valuation upside absent clearer top‑line acceleration — a reason some investors remain cautious despite the beat. Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside

Wall Street Analyst Weigh In

TXG has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft set a $17.00 target price on 10x Genomics and gave the company a “hold” rating in a research note on Friday. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Monday, December 22nd. Barclays increased their price objective on shares of 10x Genomics from $17.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Piper Sandler boosted their target price on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.61.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the completion of the sale, the insider owned 432,605 shares in the company, valued at approximately $8,219,495. The trade was a 1.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $251,959.00. Following the completion of the transaction, the chief executive officer owned 1,021,556 shares in the company, valued at $19,409,564. The trade was a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 33,432 shares of company stock worth $635,208. 9.39% of the stock is currently owned by company insiders.

Institutional Trading of 10x Genomics

Large investors have recently bought and sold shares of the company. Foundations Investment Advisors LLC acquired a new stake in shares of 10x Genomics during the third quarter worth $665,000. Jump Financial LLC grew its position in shares of 10x Genomics by 130.2% during the 2nd quarter. Jump Financial LLC now owns 1,041,051 shares of the company’s stock valued at $12,055,000 after buying an additional 588,769 shares during the last quarter. AlphaQuest LLC raised its stake in 10x Genomics by 234.3% during the third quarter. AlphaQuest LLC now owns 133,419 shares of the company’s stock worth $1,560,000 after acquiring an additional 93,514 shares during the period. Friedenthal Financial acquired a new stake in 10x Genomics during the third quarter worth about $924,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in 10x Genomics in the third quarter worth about $1,179,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Stock Up 12.5%

The stock has a 50 day simple moving average of $18.66 and a 200 day simple moving average of $15.57. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of -31.77 and a beta of 2.24.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.